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Abstract
Cutaneous melanoma (CM) is a malignancy with increasing occurrence. Its microRNA repertoire has been defined in
a number studies, leading to candidates for biological and clinical relevance: miR-200a/b/c, miR-203, miR-205, miR-204,
miR-211, miR-23b and miR-26a/b. Our work was aimed to validate the role of these candidate miRNAs
in melanoma, using additional patients cohorts and in vitro cultures. miR-26a, miR-204 and miR-211 were more
expressed in normal melanocytes, while miR-23b, miR-200b/c, miR-203 and miR-205 in epidermis and keratinocytes. None
of the keratinocyte-related miRNAs was associated with any known mutation or with clinical covariates in melanoma.
On the other hand, the loss of miR-204 was enriched in melanomas with NRAS sole mutation (Fisher exact test, P = 0.001,
Log Odds = 1.67), and less frequent than expected in those harbouring CDKN2A mutations (Fisher exact test, P = 0.001,
Log Odds − 1.09). Additionally, miR-204 was associated with better prognosis in two independent melanoma cohorts and
its exogenous expression led to growth impairment in melanoma cell lines. Thus, miR-204 represents a relevant
mechanism in melanoma, with potential prognostic value and its loss seems to act in the CDKN2A pathway, in
cooperation with NRAS.
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Results and discussion
Key microRNAs in melanoma and normal epidermis
In previous studies some microRNAs have been shown
to play a role in CM: miR-200a/b/c, miR-203 and miR-
205 were negatively associated with tumor progression
and have been proposed to slow down cell replication,
migration and invasion in vitro, inhibiting anchorage-
independent colony formation and epithelial-
mesenchymal transition (EMT). [1, 2] Furthermore,
miR-204, miR-205, miR-211, miR-23b and miR-26a/b
were highly expressed in nevi [3] and miR-211 was pro-
posed to enable a tumor suppressive function by itself
or via its host gene, TRPM1 [1, 4–7]. On the opposite
side, miR-211 is present in melanosomes produced
by melanocytes, and it could increase melanoma
invasiveness by the activation of MAPK in cancer-
associated fibroblasts [8].
Our work was aimed to re-evaluate and validate these
candidate miRNAs, using additional patients cohorts
and in vitro cultures. Eighty samples, including 15 pairs
of matched primary/metastatic tumours, 12 normal skin
biopsies, 11 cultured melanocytes, 10 cultured keratino-
cytes, and 17 melanoma cell lines were analyzed on
miRNA microarrays, as previously reported microRNA
OSU microarrays [9]. The table with quantile normal-
ized miRNA expression (log2 RPM) is reported in
Additional file 1. We identified 157 highly variable miR-
NAs (Additional file 2: Figure S1). Among the candidate
miRNAs, miR-204 and miR-211 were significantly more
expressed in cultured melanocytes than in keratinocytes
and epidermis (Fig. 1 and Additional file 2: Figure S1), but
much less in primary tumours and metastasis, in agree-
ment with previous reports [1, 3, 5, 7]. On the opposite,
miR-23b, miR200b/c, miR-203 and miR-205 [10] were
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significantly more expressed in epidermis and cultured
keratinocytes than in cultured melanocytes, but also de-
tected at low levels in primary melanoma samples. miR-
26a had only 2-fold higher levels in melanocytes than in
keratinocytes, and 2-fold lower in melanoma samples. In
order to validate and extend our findings we needed and
independent melanoma cohort, thus went on to further
investigate all non-coding RNAs in the TCGA melanoma
cohort (n = 452, Additional file 3: Table S1; http://fire-
browse.org). The TCGA consortium described three
mRNA-based subclasses in melanoma [11]: the so-called
“immune”, “MITF-low” and “keratin”. Two major findings
arose from working on the TCGA dataset. First, miR-
200c, miR-203 and miR-205 were the three miRNAs
having highest correlation with keratinocyte marker
Keratin 5 (KRT5) mRNA (Pearson r = 0.68, r = 0.61 and
r = 0.77, P < 1e-07) and miR-203/− 205 were sufficient
to identify the samples belonging to the “keratin” sub-
type (Additional file 4: Figure S2); secondly, two
markers used to identify melanoma cells, MITF and
MLANA, showed no correlation with miR-200b/c,
miR-203 and miR-205, while negatively associating with
miR-204 (r = − 0.2 and r = − 0.21, both P < 0.001, respect-
ively), and positively with miR-211 (r = 0.71 and r = 0.69,
both P < 1e-07; Additional file 5: Table S2). To better com-
prehend these findings, we studied keratins in melanoma
cell lines and patient-derived melanoma xenografts
(PDXs) [12]: only few samples showed expression of
KRT5, and at very low levels. Conversely, and as expected,
MITF and MLANA were strongly expressed in all melan-
oma cell lines and PDXs (Additional file 6: Figure S3).
Thus, miR-200c, miR-203 and miR-205 were likely due to
keratinocytes present within melanoma biopsies, both in
TCGA and in our human samples. Reassuringly, the
remaining candidate miRNAs had low (miR-23a) or no
correlation with KTR5 (miR-204, miR-211, miR-26b).
Thus, MITF showed positive association with miR-211 but
not with miR-204. This finding was in line with MITF tran-
scriptional up-regulation of host gene TRPM1 that thus in-
directly drives the expression of miR-211. Our results show
that the detection of miR-200c, miR-203 and miR-205 in
melanoma samples was likely due to presence of keratino-
cytes within the biopsies.
The expression of candidate miRNAs and somatic
melanoma mutations
BRAF and NRAS are frequently somatically mutated in
melanoma [11, 13, 14], along with NF1, CDKN2A
Fig. 1 miRNA expression in melanoma and related cell types. Box-plots of miRNA expression are shown for candidate miRNAs (OSUMC microarrays). The
y axis displays the quantiles normalized expression levels (log 2 scale); the different cell types are aligned on the x axis. The first three categories on the left
are normal controls: epidermis (EP), cultured keratinocytes (KC) and cultured melanocytes (MC). The melanoma subgroups follow, in an order
related to cancer progression: primary tumors (PR), melanoma metastasis (ME), low passage number (MT) and high passage number (CL) metastatic
melanoma cell lines
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(mutation and deletion), and CCND1 (amplification).
Thus, we tested the miRNA expression in relation with
these somatic alterations. Melanomas were split into 7
groups according to the most frequent mutation
patterns: BRAF only (n = 57), sole NRAS (n = 37), NF1
only (n = 18), BRAF and CDKN2A (n = 59), non-sole
NRAS (n = 42), remaining mutation patterns (n = 32),
and no somatic events in any of the above-mentioned
genes (n = 29) (Additional file 7: Table S3). Levels of
miR-204 and miR-211 were strongly associated with
somatic mutations, and with different trends
(Additional file 8: Figure S4). The expression of miR-204
was lost in the sole NRAS mutated and in all wild-type
tumours, while that of miR-211 was lower in the BRAF/
CDKN2A double hits (Holm adjusted P < 0.05), as
shown in Fig. 2A (see also Additional file 9: Figure S5).
As controls miR-203, miR-205 and MITF RNA levels are
invariant in the mutation subgroups (Additional file 10:
Table S4). In particular, miR-204 loss was more frequent
in sole NRAS than in non-sole NRAS (Fisher exact test,
P = 0.001, Log Odds Ratio = 1.67). On the contrary, loss
miR-204 expression was less frequent than expected in
Fig. 2 miR-204 expression in the melanoma mutation context and its association with overall survival. a) miR-204 and miR-211 log ratios plotted
(y-axes) according to somatic mutation patterns. b) The Kaplan Meyer curve shows overall survival of melanoma patients divided according to
miR-204 median level (continuous line: high miR-204; dashed line: low miR-204), in the TCGA cohort (n = 399, Log- Rank P < 0.01). The numbers of
patients at risk are reported for each of the curves at the time range under the x-axis (expressed in months)
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conjunction with homo-deleted or double compounded
heterozygote CDKN2A when compared with wild type
(Fisher exact test P = 0.001, Log Odds Ratio = − 1.09).
The remaining miRNAs were not associated with any
mutation group.
The association of candidate miRNAs with clinical
parameters in melanoma patients
We then investigated the prognostic potential of the
candidate miRNAs. miR-204 was the only miRNA asso-
ciated with prognosis in the TCGA cohort (n = 399),
where its expression loss had a negative effect on
survival (Additional file 7: Table S3). Figure 2B shows
the Kaplan Meyer curve for miR-204 in overall survival
(OS) for all patients (Cox regression odds ratio [OR],
0.71; 95% CI, 0.53–0.95 P = 0.02; Log Rank test on the
median expression, P = 0.016). Furthermore, since miR-
204 was down regulated in specific mutation subsets
(Additional file 10: Table S4) we investigated its impact
on survival in those contexts. The independent value of
miR-204 was shown by a multivariate Cox regression,
where the mutation subsets were confounding factors
(Additional file 11). We validated the association of miR-
204 with survival in an independent cohort of 32 melan-
oma samples (OSUMC), by using the TaqMan Array
RT-PCR platform. The patients were divided in two
groups by their median survival time (median OS =
7 years). The miR-204 expression was lower in samples
with poor prognosis (t-test, P < 0.05), confirming the
results of the TCGA cohort.
Finally, we studied the miRNAs in the Breslow’s stages,
related with tumour invasion in the dermal layer.
miR-204 and miR-211 expression correlated with
Breslow’s thickness, with opposite, albeit not strong,
trends: miR-211 was positively correlated (Spearman ρ= 0.2,
P < 0.001, n = 309), while miR-204 had the negative cor-
relation expected for its role on survival (ρ=− 0.13, P < 0.02,
n = 309). Similar results were obtained using a trend-test ra-
ther than Spearman correlation (Additional Informa-
tion). Among the miRNAs we evaluated in melanoma,
only miR-204 and miR-211 were associated with
important clinical parameters. Intriguing is the finding
that miR-204 and miR-211 had an opposite relationship
with Breslow’s stages. Our hypothesis is that melanoma
cells expressing miR-204 and those expressing miR-211
belong to two subtypes with different invasive potential.
This hypothesis is supported by the differences in mu-
tation profiles we identified in the TCGA samples ex-
pressing the two miRNAs. Furthermore, a very recent
work [15] shows that miR-204 is under the control of
STAT3 and its expression is induced in amelanotic
melanoma cells, where it can act as an effector of
vemurafenib’s anti-motility activity. Conversely, miR-
211 is induced in melanotic melanoma cells and serves
as an effector of vemurafenib’s pro-pigmentation activ-
ity. It becomes thus more apparent a pro-invasiveness
role for miR-211, as Dror et al. [8] described with
melanosomal miR-211 directly targeting IGF2R and
leading to MAPK signalling activation in cancer associ-
ated fibroblasts.
miR-204 and miR-211 can inhibit growth in melanoma cell
lines
miR-204 and miR-211 share the same seed sequence,
but their expression levels were inversely correlated be-
tween themselves (Pearson r = − 0.25, P < 1e-07) and
with MITF and MLANA melanocytic markers. Further-
more miR-204 and miR-211 had opposite behaviours in
somatic mutation groups, in Breslow’s depth and in
prognosis. To study the miRNAs’ roles in vitro, we
investigated their impact on five melanoma cell lines:
MDA-MB-435, G361, VAG, Me-1007 and COLO38, dif-
fering for their BRAF and CDKN2A mutation patterns
(Additional file 12: Table S7). miR-204 and miR-211
mimics were transiently transfected to assess their
impact on cell viability (Fig. 3). VAG and Me-1007, har-
bouring no mutations in BRAF and CDKN2A, were
sensitive to both miRNAs. On the contrary, doubly
mutated G361 was insensitive to both miRNAs. Only
miR-204 mimic inhibited MDA-MB-435, harbouring
BRAF V600E and a CDKN2A splicing mutation, while
only miR-211 inhibited Colo-38, a cell line mutated in
BRAF but not in CDK2A. In summary, either miR-204
or miR-211 mimics inhibited cell growth in cell lines
Fig. 3 Exogenous miR-204 and miR-211 and cell growth in melanoma
cell lines. The box-plots represent the relative cell growth inhibition
upon transfection of miR-204 and miR-211 in five melanoma cell lines.
MTS assays were baseline subtracted from control and normalized, as
described in the supplementary methods (Additional file 15). The blue
shaded cell lines were BRAF mutated and the orange were BRAF wild
type. No cell line among those treated harbored an NRAS mutation
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carrying wild type but not in those with a mutated BRAF
(t-test, P < 0.01). In agreement with our findings, Dia-
z-Martinez and coworkers very recently showed that ec-
topic expression of both miRNAs was sufficient to
augment in vivo tumor growth of A375 cells [16], that
like G361 are BRAF/CDKN2A doubly mutated. These
two related miRNAs share the same conserved seed, but
their expression was inversely correlated when compared
to melanocytic markers MITF and MLANA. miR-204
was significantly down-regulated in melanoma with wild
type BRAF/NRAS or with sole NRAS mutation, as sum-
marized in Additional file 13: Figure S6. In vitro, both
miRNAs can inhibit growth of melanoma cell lines, and
they seem to exert either equal (for example on BRAF/
CDKN2A double wild type Me-1007 and VAG cell lines)
or differential activity. It is possible that the common in-
hibition is exerted via the conserved seed, while the
differential activity of the two miRNAs is due to the
non-seed sequences. In fact, the miRanda database of
predicted targets (http://microRNA.org at MSKCC),
reports 3397 common predicted targets, 239 specific for
miR-211 and 220 specific for miR-204 (Additional file 14:
Table S8). On the other hand, when the two miRNAs
are expressed in different mutation backgrounds, it is
also possible that their effects, although mediated by the
common seed, impact onto different targets. Of note,
the loss of miR-204 expression was described in glioma,
also thought to derive from a neural type precursor,
where it led to an increase in cell migration and to a
stem cell-like phenotype [17]. Furthermore, miR-204
was described as a key regulator of MMP9 and BCL2 in
a xenograft model of melanoma [18].
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